Dova Pharmaceuticals Inc., a clinical, late-stage company, recently named Alex Sapir as its new CEO.
Sapir kicked off his duties by presenting a corporate update at the 35th Annual J.P. Morgan Healthcare Conference in California last week.
Sapir brings more than 20 years of pharmaceutical experience to the table, most recently at United Therapeutics, where he acted as executive vice president of marketing and sales. Over a 10-year period, Sapir helped the company grow from a $100 million annual revenue business to one that brings in $1.6 billion annually. Before United Therapeutics, Sapir was a consultant with ZS Associates.
Sapir will oversee Dova’s transition from late-stage clinical development to NDA submission and hopeful commercial launch. He received a bachelor of arts in economics from Franklin and Marshall College and an MBA from Harvard Business School.
Dova Pharmaceuticals focuses on the development of drugs for patients dealing with orphan diseases, which are defined as those affecting fewer than 200,000 people in the United States.